[Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
A new buflomedil retard preparation has been evaluated in 318 patients, suffering from obliterating arterial disease of the lower limbs, for 90 days at once daily 600 mg doses. After 30 days of treatment a significant (p less than 0.001) improvement of paresthesia, hypothermia and "claudicatio intermittens" has been found. The same trend has been found after 90 days with improvement of walking distance (+ 81.1%), walking time (+ 62.1%), walking speed (+ 15.0%) as well as a significant decrease of functional recovery time (-24.6%). The AA. stress the good tolerability and compliance of this new retard preparation.
Andreozzi
G M
GM
Cattedra di Angiologia, Università degli Studi di Catania.
Lepore
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D011759:Pyrrolidines; D014665:Vasodilator Agents; C010651:buflomedil
Attività e tollerabilità di buflomedil ritardo nelle arteriopatie obliteranti degli arti inferiori. Studio policentrico.